Rasburicase — Drug Intelligence | 7 EU Trials

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

4 Completed trials

6 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 3 Phase II: 1 Phase I/II: 2 Phase I (FiH): 1

Oversight events:

2 urgent safety measures 2 unexpected events across 3 trials

View oversight register →

Indications tested

Acute myeloid leukaemia recurrent 1 Myelodysplastic syndrome transformation 1 Follicular lymphoma 1 Chronic myelomonocytic leukaemia 1 Acute myeloid leukaemia refractory 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 2 Assistance Publique Hopitaux De Paris 1 Fondazione Gimema Franco Mandelli Onlus 1 Heinrich-Heine-Universitaet Duesseldorf 1 Institut De Recherches Internationales Servier IRIS 1 LYSARC 1

All trials

7 total

RASBU-SEPSIS Study: Effects of rasburicase on kidney during sepsis – a randomized, placebo-controlled, double-blind trial Pending

2023-508071-36-00 Phase III 1 country Assistance Publique Hopitaux De Paris
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Phase III 6 countries Lysarc
Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting

2024-514688-24-00 Phase I/II 1 country Heinrich-Heine-Universitaet Duesseldorf
Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended

2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
A study to evaluate S227928 as a Single Agent and in Combination with Venetoclax in Patients with R/R AML, MDS/AML, or CMML Ended

2024-514356-33-00 Phase I (FiH) 3 countries Institut De Recherches Internationales Servier IRIS
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Phase III 11 countries F. Hoffmann-La Roche AG

Showing 1–7 of 7 trials

← All drugs A–Z